(ČIA) In 2021, AstraZeneca Czech Republic will focus on bringing innovative medicinal products in the field of oncology, cardiovascular and respiratory biology. The annual report also shows that in 2020 it achieved a net turnover of CZK 1.43bn. Profit after tax amounted to CZK 29.23mn. The main drivers of sales were Symbicort, Lynparza, Xigduo, and Forxiga. The company has conducted 16 clinical trials and studies. In the pandemic year, the pharmaceutical company accelerated the advent of digital communication tools.